Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

AirNexis Therapeutics launches with $200M tranched Series A targeting COPD

by mariel | Mar 3, 2026 | Portfolio News

CG Oncology accelerates Phase 3 PIVOT-006 readout to H1 2026

by mariel | Feb 27, 2026 | Portfolio News

FDA grants Priority Review to Vera Therapeutics’ BLA for atacicept in IgA nephropathy; PDUFA date July 7, 2026; completes $800M combined equity and debt financing to support commercial readiness

by mariel | Feb 26, 2026 | Portfolio News

OrsoBio reports positive Phase 2a proof-of-concept results for TLC-2716 in hypertriglyceridemia and MASLD

by mariel | Feb 10, 2026 | Portfolio News

Veradermics completes IPO; begins trading on NYSE under ticker “MANE”

by mariel | Feb 4, 2026 | Portfolio News

Veradermics closed an oversubscribed Series C in 4Q25 and subsequently completed its IPO, with shares beginning to trade under ticker MANE.

Epirium Bio reports positive Phase 1 MF-300 data in sarcopenia; receives favorable FDA guidance for Phase 2b

by mariel | Jan 27, 2026 | Portfolio News

Boston Scientific completes acquisition of Nalu Medical

by mariel | Jan 27, 2026 | Portfolio News

Nalu’s acquisition by Boston Scientific was completed after quarter-end; LVP2 reported receiving $26.4mm in proceeds.

IntelyCare acquires CareRev to expand clinical labor solutions across acute and post-acute care

by mariel | Jan 8, 2026 | Portfolio News

IntelyCare completed the acquisition of CareRev, creating a broader workforce platform; the combined business generated >$200M pro forma revenue in CY2025.

Zenas BioPharma reports positive Phase 3 INDIGO registrational results for obexelimab in IgG4-RD

by mariel | Jan 5, 2026 | Portfolio News

Zenas reported positive Phase 3 INDIGO results and indicated plans to submit a BLA in 2Q26 and MAA in 2H26.

Viridian announces FDA acceptance and Priority Review for veligrotug BLA in thyroid eye disease

by mariel | Dec 22, 2025 | Portfolio News

Viridian submitted its BLA in TED and subsequently announced the BLA received Priority Review with a PDUFA target action date of June 30, 2026.
« Older Entries
Next Entries »

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • X
  • RSS
footer-logo

LP Login

© 2026 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer